2010
Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial
Rosenheck R, Davis S, Covell N, Essock S, Swart M, Stroup S, McEvoy J, Lieberman J. Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2010, 8: 561-569. DOI: 10.1176/foc.8.4.foc561.Peer-Reviewed Original ResearchGreater weight gainNew medicationsOutcome measuresWeight gainNeurological side effectsAdditional outcome measuresPotential confounding factorsQuality of lifeStudy drugPrevious medicationCATIE trialMultivariate adjustmentImprove OutcomesMedicationsSide effectsOlanzapinePatientsConfounding factorsDrugsHealth costsOutcomesSignificant differencesRisperidoneCATIEMixed models
2006
Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos M, Glick I, Miller A, Hamner M, Miller D, Patel J, Tapp A, Keefe R, Rosenheck R. Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. Psychiatric Services 2006, 57: 1094-1101. PMID: 16870959, DOI: 10.1176/ps.2006.57.8.1094.Peer-Reviewed Original ResearchConceptsConcomitant psychotropic medicationsPsychotropic medicationsConcomitant medication useIntervention Effectiveness (CATIE) trialOnly partial responseSecond-generation antipsychoticsBetter neurocognitive functioningClinical Antipsychotic TrialsPartial responseCATIE trialMedication useAnticholinergic drugsBaseline useMedication dataMood stabilizersCases symptomsConcomitant useEffectiveness trialAntipsychotic TrialsMedicationsNeurocognitive functioningSchizophreniaBaseline dataTrialsAntipsychotics